Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma
NCT06327269
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
RECRUITING
Status
40
Enrollment
OTHER
Sponsor class
Conditions
High Risk of Recurrence
Interventions
DRUG:
Lenvatinib 10 mg
Sponsor
Chang Gung Memorial Hospital
Collaborators
[object Object]